Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking in with an expert on the immuno-oncology landscape in metastatic triple-negative breast cancer and where IMMU-132 fits in after the 2017 SABCS conference last week

Ticker(s): IMMU, MRK

Who's the expert?

Name: Dr Daniel P Silver - MD, PhD

Institution: Sidney Kimmel Cancer Center

  • Leader, Breast Program Sidney Kimmel Cancer Center & Associate Professor and Director, Basic Science and Research in Medical Oncology
  • Treats ~400 patients with breast cancer/year, currently treats ~12 with metastatic triple-negative breast cancer and has treated hundreds with mTNBC in the last 20 years.
  • Attended SABCS and very familiar with the data from the Phase 2 trial for Sacituzumab Govitecan (IMMU-132)

Interview Questions
Q1.

Please describe your clinical practice; roughly how many patients with triple-negative breast cancer do you currently treat

Added By: c_admin
Q2.

What were your impressions on the data presented at SABCS for Sacituzumab govitecan (IMMU-132)?

Added By: c_admin
Q3.

If approved, how do you see IMMU-132 competing in the IO landscape? How does it compare to Keytruda?

Added By: c_admin
Q4.

On a scale of 1-10, 10 being extremely excited, where would you rate your level of excitement for this drug?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.